Repurposing FDA-Approved Antimalarial Drugs: Mefloquine As a Promising Multi-Targeted Therapeutic for Non-Small Cell Lung Cancer: Repurposing Antimalarials: Mefloquine for Multi-Targeted NSCLC Therapy. IJC 2025, 64 (7), 730-745. https://doi.org/10.56042/ijc.v64i7.16642.